Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARCT Arcturus Therapeutics Ltd.

Trading 05-22 14:15:08 EDT

32.10

+2.25

+7.54%

High32.50	Low29.22	Vol286.31K
Open29.70	D1 Closing29.85	Amplitude10.99%
Mkt Cap864.51M	Tradable Cap788.88M	Total Shares26.93M
T/O8.92M	T/O Rate1.17%	Tradable Shares24.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ARCT","market":"US","secType":"STK","nameCN":"Arcturus Therapeutics Ltd.","latestPrice":32.1,"timestamp":1716401701699,"preClose":29.85,"halted":0,"volume":286314,"delay":0,"floatShares":24575654,"shares":26931826,"eps":-4.023774,"marketStatus":"Trading","change":2.25,"latestTime":"05-22 14:15:08 EDT","open":29.7,"high":32.5,"low":29.22,"amount":8923163.34567,"amplitude":0.109883,"askPrice":32.14,"askSize":117,"bidPrice":32.08,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.023774,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1716408000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":29.85,"preHourTrading":{"tag":"盘前","latestPrice":29.68,"preClose":29.85,"latestTime":"09:29 EDT","volume":3,"amount":92.03999999999999,"timestamp":1716384599996},"postHourTrading":{"tag":"盘后","latestPrice":29.85,"preClose":29.85,"latestTime":"17:23 EDT","volume":10295,"amount":307296.95,"timestamp":1716326624438},"volumeRatio":1.257918},"requestUrl":"/m/hq/s/ARCT","defaultTab":"news","newsList":[{"id":"2437211045","title":"COVID-19 vaccine makers rebound amid post-pandemic prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2437211045","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2437211045?lang=en_us&edition=fundamental","pubTime":"2024-05-23 02:00","pubTimestamp":1716400826,"startTime":"0","endTime":"0","summary":"Shares of Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), and Novavax (NASDAQ:NVAX) are continuing a recent upswing as investors look for their post-pandemic growth trajectory amid d","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253358164/image_1253358164.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253358164/image_1253358164.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4109471-covid-19-vaccine-makers-gain-post-pandemic-prospects","is_publish_highlight":false,"gpt_icon":0},{"id":"2437291899","title":"Achilles Therapeutics Collaborating With Arcturus Therapeutics to Evaluate mRNA Personalized Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2437291899","media":"MT Newswires Live","top":-1,"share":"https://ttm.financial/m/news/2437291899?lang=en_us&edition=fundamental","pubTime":"2024-05-22 22:26","pubTimestamp":1716387972,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"gpt_icon":0},{"id":"2437263028","title":"Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines","url":"https://stock-news.laohu8.com/highlight/detail?id=2437263028","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2437263028?lang=en_us&edition=fundamental","pubTime":"2024-05-22 11:00","pubTimestamp":1716346800,"startTime":"0","endTime":"0","summary":"Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durabl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/22/2886352/0/en/Achilles-Therapeutics-Announces-Research-Collaboration-with-Arcturus-Therapeutics-to-Explore-Second-Generation-Personalized-mRNA-Cancer-Vaccines.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2436170146","title":"Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2436170146","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2436170146?lang=en_us&edition=fundamental","pubTime":"2024-05-20 20:30","pubTimestamp":1716208200,"startTime":"0","endTime":"0","summary":"Data follow the approval of the world's first self-amplifying  COVID-19 vaccine for adults in Japan.These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster.KING OF PRUSSIA, Pa. and SAN DIEGO, May 20, 2024 /PRNewswire/ --Global biotechnology leaderCSL  and Arcturus Therapeutics  today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying  COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.The results demonstrate that two 5 μg doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19. The efficacy of ARCT-154 against severe COVID-19 ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0yTvG6RCLk9Hr.kDeMk9aA--~B/aD0zNDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f57d6417ee02a6b52d9a87c500485e01","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0yTvG6RCLk9Hr.kDeMk9aA--~B/aD0zNDE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f57d6417ee02a6b52d9a87c500485e01"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nature-communications-publishes-pivotal-data-123000941.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nature-communications-publishes-pivotal-data-123000941.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435667955","title":"Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2435667955","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2435667955?lang=en_us&edition=fundamental","pubTime":"2024-05-16 04:01","pubTimestamp":1715803260,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May 15, 2024----Arcturus Therapeutics Holdings Inc. , a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor and scientific conferences:. H.C. Wainwright 2nd Annual BioConnect Investor Conference as NASDAQ . IR and Media Contacts Arcturus TherapeuticsNeda SafarzadehVP, Head of IR/PR/Marketing 900-2682IR@ArcturusRx.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ydZlxEH.ati727WZjrw.Jw--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/6346c5668655a5a340ef1e76b40e744b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ydZlxEH.ati727WZjrw.Jw--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/6346c5668655a5a340ef1e76b40e744b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-attend-upcoming-investor-200100930.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434333260","title":"Arcturus Therapeutics (NASDAQ:ARCT) Making Significant Strides Towards Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2434333260","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434333260?lang=en_us&edition=fundamental","pubTime":"2024-05-12 17:06","pubTimestamp":1715504780,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics (NASDQ:ARCT) is making significant strides across different aspects of its operations. The company’s collaboration with Meiji...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/arcturus-therapeutics-nasdaqarct-making-significant-strides-towards-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/arcturus-therapeutics-nasdaqarct-making-significant-strides-towards-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434147710","title":"Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2434147710","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2434147710?lang=en_us&edition=fundamental","pubTime":"2024-05-09 23:13","pubTimestamp":1715267583,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter .Operator: Good afternoon, ladies and gentlemen, and welcome to the Arcturus Therapeutics First Quarter 2024 Earnings Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions]. This call is being recorded on Wednesday, May 8, 2024. I would now like to turn the conference over to Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations & Marketing of Arcturus Therapeutics. Please go ahead.We were pleased to see yet again a superior immunogenicity and neutralizing antibod","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5wptGPpITOozMDVUNSZx9Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d27550770a7f77135d3a5312616d88a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5wptGPpITOozMDVUNSZx9Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/d27550770a7f77135d3a5312616d88a0"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-holdings-inc-nasdaq-151303857.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434988620","title":"Piper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434988620","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434988620?lang=en_us&edition=fundamental","pubTime":"2024-05-09 18:54","pubTimestamp":1715252068,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a pri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-arcturus-therapeutics-arct?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-arcturus-therapeutics-arct?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434509050","title":"Arcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2434509050","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2434509050?lang=en_us&edition=fundamental","pubTime":"2024-05-09 15:48","pubTimestamp":1715240925,"startTime":"0","endTime":"0","summary":"Revenue: Q1 2024 revenue was $38 million, up from $30.9 million in Q4 2023.Net Loss: Reported a net loss of $26.8 million in Q1 2024, compared to a net loss of $11.7 million in Q4 2023.Earnings Per Share: Net loss per diluted share was $1 in Q1 2024 versus $0.44 in Q4 2023.Operating Expenses: Total operating expenses were $68.4 million in Q1 2024, up from $49.1 million in Q4 2023.Research and Development Expenses: R&D expenses increased to $53.6 million in Q1 2024 from $36.6 million in Q4 2023.Cash Position: Cash, cash equivalents, and restricted cash totaled $345.3 million as of March 31, 2024.Commercial Milestones: Anticipated delivery of 4 million doses of COVID-19 vaccine to Japan in Q3 2024, marking the initiation of commercial sales.GuruFocus has detected 6 Warning Signs with ARCT.Arcturus reported a revenue increase to $38 million in Q1 2024 from $30.9 million in Q4 2023, driven by increased activity across its CSL program.Total operating expenses increased to $68.4 million in Q","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-holdings-inc-arct-074845993.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434270454","title":"Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2434270454","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2434270454?lang=en_us&edition=fundamental","pubTime":"2024-05-09 04:01","pubTimestamp":1715198460,"startTime":"0","endTime":"0","summary":"Commercial manufacture of Kostaive on track for delivery of initial 4 million doses in Q3. Kostaive European Marketing Authorization Application approval decision expected Q3. Multiple Kostaive Phase 3 trials further demonstrate breadth and durability of STARR vaccine platform. ARCT-2138  Phase 1 topline immunogenicity and safety data, anticipated in Q3. ARCT-810  Phase 2 and ARCT-032  Phase 1b interim data and update to be provided on July 1st. JP Morgan engaged to monetize investment in ARCALIS JV in Japan. \"Arcturus continues to make encouraging progress in both our vaccine and therapeutics pipeline,\" said Joseph Payne, President & CEO of Arcturus. \"In collaboration with our global vaccine partner CSL and their partner Meiji Seika Pharma, we are excited to begin the commercialization of Kostaive this year.\". In March, Meiji Seika Pharma announced plans to supply Japan with 4 million doses of Kostaive for fall/winter season of 2024. To support this effort, Arcturus along with CDMO pa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/m4ZsFqPVJIDHebJLIKXaWA--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/71f157a3f59288dfdea5fddf09a75e7a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/m4ZsFqPVJIDHebJLIKXaWA--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/71f157a3f59288dfdea5fddf09a75e7a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-announces-first-quarter-200100200.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433432827","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2433432827","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2433432827?lang=en_us&edition=fundamental","pubTime":"2024-05-08 18:00","pubTimestamp":1715162400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Airbnb Inc. Class A                              1Q       .23   4:05 PM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2432139970","title":"BioNTech: Undecided Between A One Trick Pony And A Full-Fledged Pharma Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2432139970","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432139970?lang=en_us&edition=fundamental","pubTime":"2024-05-03 21:31","pubTimestamp":1714743116,"startTime":"0","endTime":"0","summary":"BioNTech is a biotech company with a strong cash position and a commercial program generating cash flow, making it a promising investment opportunity.The company's pipeline includes programs targeting","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307139993/image_1307139993.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4689022-biontech-undecided-between-a-one-trick-pony-and-a-full-fledged-pharma-company","is_publish_highlight":false,"gpt_icon":0},{"id":"2432507485","title":"Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for","url":"https://stock-news.laohu8.com/highlight/detail?id=2432507485","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432507485?lang=en_us&edition=fundamental","pubTime":"2024-05-01 22:01","pubTimestamp":1714572088,"startTime":"0","endTime":"0","summary":"Wall Street expects a year-over-year decline in earnings on lower revenues when Arcturus Therapeutics  reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 8. On the other hand, if they miss, the stock may move lower.While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.This pharmaceutical company is expected to post quarterly loss of $1.17 per share in its upcoming report, which represents a year-over-year change of -233%.Revenues are expe","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fj4TPQveJWuth16WIsEVAw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/46ebfcbff417ac1bbde85ad33fa0d4be"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/analysts-estimate-arcturus-therapeutics-arct-140128199.html","is_publish_highlight":false,"gpt_icon":1},{"id":"2432853876","title":"Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2432853876","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2432853876?lang=en_us&edition=fundamental","pubTime":"2024-05-01 04:42","pubTimestamp":1714509720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Vertex Pharmaceuticals Inc.  dropped 0.86% to $392.81 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 1.57% to 5,035.69 and Dow Jones Industrial Average  falling 1.49% to 37,815.92.This was the stock's fifth consecutive day of losses.Vertex Pharmaceuticals Inc. closed $55.59 short of its 52-week high , which the company reached on January 30th.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as AbbVie Inc.  rose 0.69% to $162.64, Krystal Biotech Inc.  fell 3.08% to $153.12, and Arcturus Therapeutics Holdings Inc.  fell 3.98% to $25.57.Trading volume  eclipsed its 50-day average volume of 979,405.Data source: Dow Jones Market Data, FactSet. Data compiled April 30, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is publis","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2431862041","title":"Arcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284% return over the last five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2431862041","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2431862041?lang=en_us&edition=fundamental","pubTime":"2024-04-29 22:11","pubTimestamp":1714399880,"startTime":"0","endTime":"0","summary":"It might be of some concern to shareholders to see the Arcturus Therapeutics Holdings Inc.  share price down 21% in the last month. But in stark contrast, the returns over the last half decade have impressed. Indeed, the share price is up an impressive 284% in that time. To some, the recent pullback wouldn't be surprising after such a fast rise. Only time will tell if there is still too much optimism currently reflected in the share price.With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.See our latest analysis for Arcturus Therapeutics Holdings. Arcturus Therapeutics Holdings wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share . Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's becaus","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-holdings-nasdaq-arct-141120751.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430252798","title":"Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2430252798","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2430252798?lang=en_us&edition=fundamental","pubTime":"2024-04-26 04:01","pubTimestamp":1714075260,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 25, 2024----Arcturus Therapeutics Holdings Inc. , a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended March 31, 2024 after the market close on Wednesday, May 8 and will also host a conference call and webcast at 4:30 pm Eastern Time on May 8, 2024.Arcturus Therapeutics First Quarter 2024 Earnings Conference Call. IR and Media Contacts Arcturus TherapeuticsNeda SafarzadehVP, Head of IR/PR/MarketingIR@ArcturusRx.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UoUYtvtBJHHw8rrbYU2mhw--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/d93fffe6d2b7167ea35743f2457a876f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UoUYtvtBJHHw8rrbYU2mhw--~B/aD0xMzIwO3c9MzYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/d93fffe6d2b7167ea35743f2457a876f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-therapeutics-report-first-quarter-200100867.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429164803","title":"Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2429164803","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2429164803?lang=en_us&edition=fundamental","pubTime":"2024-04-23 18:01","pubTimestamp":1713866476,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics' ARCT-032 gene therapy for cystic fibrosis has been designated as an \"orphan drug\" in the U.S. and Europe.The therapy has the potential to generate significant revenues, similar ","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1567313134/image_1567313134.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1567313134/image_1567313134.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4685225-arcturus-therapeutics-arct-032-might-be-the-next-breakthrough-in-cystic-fibrosis","is_publish_highlight":false,"gpt_icon":0},{"id":"2428168466","title":"Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2428168466","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428168466?lang=en_us&edition=fundamental","pubTime":"2024-04-19 15:54","pubTimestamp":1713513257,"startTime":"0","endTime":"0","summary":"ARK Invest's 13F portfolio value decreased by 15% this quarter, with the number of holdings increasing from 223 to 230.The top three holdings in the portfolio are Coinbase Global, Tesla, and Block, ma","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4684648-cathie-wood-ark-invest-13f-portfolio-q1-2024-update","is_publish_highlight":false,"gpt_icon":0},{"id":"2428877320","title":"As more rare disease therapies launch, their prices are rising","url":"https://stock-news.laohu8.com/highlight/detail?id=2428877320","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428877320?lang=en_us&edition=fundamental","pubTime":"2024-04-17 00:22","pubTimestamp":1713284570,"startTime":"0","endTime":"0","summary":"Therapies that treat rare diseases are among the most expensive treatments for patients, with price tags often reaching seven figures. Despite their high price, the treatments are usually lucrative fo","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1489211062/image_1489211062.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1489211062/image_1489211062.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4089415-more-rare-disease-therapies-launch-their-prices-rising","is_publish_highlight":false,"gpt_icon":0},{"id":"2427283932","title":"Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2427283932","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2427283932?lang=en_us&edition=fundamental","pubTime":"2024-04-16 04:43","pubTimestamp":1713213780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Vertex Pharmaceuticals Inc.  inched 0.20% higher to $397.36 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index  falling 1.20% to 5,061.82 and Dow Jones Industrial Average  falling 0.65% to 37,735.11.Vertex Pharmaceuticals Inc. closed $51.04 short of its 52-week high , which the company achieved on January 30th.The stock outperformed some of its competitors Monday, as AbbVie Inc.  fell 0.38% to $161.67, Krystal Biotech Inc.  fell 2.23% to $169.75, and Arcturus Therapeutics Holdings Inc.  fell 3.68% to $29.31.Trading volume  eclipsed its 50-day average volume of 1.2 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 15, 2024.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcturusrx.com","stockEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":0.149},{"period":"3month","weight":-0.1539},{"period":"6month","weight":0.2686},{"period":"1year","weight":0.0978},{"period":"ytd","weight":-0.0533}],"compareEarnings":[{"period":"1week","weight":0.0154},{"period":"1month","weight":0.0731},{"period":"3month","weight":0.0687},{"period":"6month","weight":0.1678},{"period":"1year","weight":0.2688},{"period":"ytd","weight":0.1179}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.080132},{"month":2,"riseRate":0.545455,"avgChangeRate":0.011691},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.021161},{"month":4,"riseRate":0.545455,"avgChangeRate":0.101832},{"month":5,"riseRate":0.636364,"avgChangeRate":0.073745},{"month":6,"riseRate":0.636364,"avgChangeRate":0.059043},{"month":7,"riseRate":0.636364,"avgChangeRate":0.122819},{"month":8,"riseRate":0.545455,"avgChangeRate":0.05911},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.078674},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.028789},{"month":11,"riseRate":0.636364,"avgChangeRate":0.065619},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.060891}],"exchange":"NASDAQ","name":"Arcturus Therapeutics Ltd.","nameEN":"Arcturus Therapeutics Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arcturus Therapeutics Ltd.,ARCT,Arcturus Therapeutics Ltd.股票,Arcturus Therapeutics Ltd.股票老虎,Arcturus Therapeutics Ltd.股票老虎国际,Arcturus Therapeutics Ltd.行情,Arcturus Therapeutics Ltd.股票行情,Arcturus Therapeutics Ltd.股价,Arcturus Therapeutics Ltd.股市,Arcturus Therapeutics Ltd.股票价格,Arcturus Therapeutics Ltd.股票交易,Arcturus Therapeutics Ltd.股票购买,Arcturus Therapeutics Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcturus Therapeutics Ltd.(ARCT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arcturus Therapeutics Ltd.(ARCT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}